India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
The Gujarat Chief Minister Bhupendra Patel has made an announcement about awarding the Vishisht Gujarat…
Reserve Bank of India has granted approval for the appointment of Anup Kumar Saha as…
Governor Gavin Newsom has approved the Assembly Bill 1267 (AB 1267), which bans child marriage…
The manufacturing sector in India saw a pick-up in September 2026, as the HSBC India…
Narendra Bhooshan, who is the 1992-batch of Indian Administrative Service (IAS) from the Uttar Pradesh…
Indian batsman Rohit Sharma crossed the 12,000 ODI runs mark in the second ODI match…